01814nas a2200325   4500000000100000008004100001260001200042653003700054100001300091700001500104700001200119700001500131700001400146700001400160700001400174700001200188700001400200700001100214700001400225700001600239700001300255700001000268700001200278245011100290856007600401300000700477490000700484520098300491022001401474       2021                            d  bMedknow10aAnesthesiology and Pain Medicine1 aNarang T1 aBhardwaj A1 aGupta S1 aSuneetha S1 aPradhan S1 aAgarwal P1 aSuvirya S1 aGupta A1 aChhabra N1 aRao AG1 aAshwini P1 aJandhyala S1 aRathod S1 aRao P1 aDogra S00aUpdates on management of leprosy in the context of COVID-19 pandemic: Recommendations by IADVL SIG Leprosy  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664173/pdf/IDOJ-12-24.pdf  a240 v123 a<p>The Special Interest Group (SIG) on leprosy thought it to be prudent to revisit its previous practice recommendations through this update. During this period, the pandemic course shifted to a ‘second wave’ riding on the ‘delta variant’. While the number of cases increased manifold, so did the research on all aspects of the disease. Introduction of vaccination and data from various drug trials have an impact on current best practices on management of diseases including leprosy. The beneficial results of using steroids in management of COVID-19, gives elbow room regarding its usage in conditions like lepra reactions. On the other hand, the increase in cases of Mucormycosis again underlines applying due caution while recommending immunosuppressants to a patient already suffering from COVID-19. This recommendation update from SIG leprosy reflects current understanding about managing leprosy while the dynamic pandemic continues with its ebbs and flows.</p>
  a2229-5178